We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Marcellinus Dordunoo
Marcellinus Dordunoo
Products
PRODUCTS
Eugia SEZ Private Ltd.
Marcellinus Dordunoo
and
Ashar P. Parikh
Price:
$117.00
View
SigmaPharm Laboratories, LLC
Marcellinus Dordunoo
and
Daniel J. Min
Price:
$117.00
View
Bell-More Laboratories, Inc.
Shirshendu K. Deb
,
Marcellinus Dordunoo
, and
Nerizza B. Guerin
Price:
$117.00
View
Pharmaceutics International, Inc.
Shirshendu K. Deb
,
Marcellinus Dordunoo
,
Kathleen Jordan
, and
Viviana Matta
Price:
$117.00
View
Emergent Manufacturing Operations Baltimore, LLC
Marcellinus Dordunoo
Price:
$117.00
View
Biocon Ltd.
Marcellinus Dordunoo
Price:
$117.00
View
Vida International, Inc.
Marcellinus Dordunoo
Price:
$117.00
View
Henan Kangdi Medical Devices Co., Ltd.
Marcellinus Dordunoo
Price:
$117.00
View
Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical
Marcellinus Dordunoo
,
Linda F. Murphy
, and
Taichun Qin
Price:
$117.00
View
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
FDA, FTC and DOJ Enforcement of Medical Device Regulations
Using Real-World Evidence in Drug and Device Submissions
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More